Europe
Bacteria do not simply perish in hunger phases fortuitously; rather, the surrounding cells have a say as well.
Summit Therapeutics plc announced that it highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat all gonorrhoea, including multi-drug and extensively-drug resistant strains, in a poster presentation at the STI & HIV World Congress in Vancouver, Canada.
Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company
Scientists at the University of Eastern Finland and the University of Oxford have shown that small RNA molecules occurring naturally in cells, i.e. microRNAs, are also abundant in cell nuclei.
Atriva Therapeutics GmbH announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME.
Karus Therapeutics Ltd, a clinical-stage biopharmaceutical company developing precision medicines for cancer, announced the appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer with immediate effect.
Vectura Group plc confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update.
Polyphor announced that it has decided to close the Phase III PRISM MDR and UDR studies of murapavadin intravenous for hospital-acquired and ventilator-associated bacterial pneumonia which have been put on a voluntary temporary hold on May 9th, 2019.
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
A disproportionate number of ALS patients on the investigational drug developed pneumonia.
PRESS RELEASES